210 related articles for article (PubMed ID: 20492467)
1. Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data.
Sorich MJ; Vitry A; Ward MB; Horowitz JD; McKinnon RA
J Thromb Haemost; 2010 Aug; 8(8):1678-84. PubMed ID: 20492467
[TBL] [Abstract][Full Text] [Related]
2. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis.
Mega JL; Close SL; Wiviott SD; Shen L; Walker JR; Simon T; Antman EM; Braunwald E; Sabatine MS
Lancet; 2010 Oct; 376(9749):1312-9. PubMed ID: 20801494
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.
Reese ES; Daniel Mullins C; Beitelshees AL; Onukwugha E
Pharmacotherapy; 2012 Apr; 32(4):323-32. PubMed ID: 22461122
[TBL] [Abstract][Full Text] [Related]
4. The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation.
Panattoni L; Brown PM; Te Ao B; Webster M; Gladding P
Pharmacoeconomics; 2012 Nov; 30(11):1067-84. PubMed ID: 22974536
[TBL] [Abstract][Full Text] [Related]
5. Effect of CYP2C19*2 and *17 genetic variants on platelet response to clopidogrel and prasugrel maintenance dose and relation to bleeding complications.
Grosdidier C; Quilici J; Loosveld M; Camoin L; Moro PJ; Saut N; Gaborit B; Pankert M; Cohen W; Lambert M; Beguin S; Morange PE; Bonnet JL; Alessi MC; Cuisset T
Am J Cardiol; 2013 Apr; 111(7):985-90. PubMed ID: 23340030
[TBL] [Abstract][Full Text] [Related]
6. Critical review of prasugrel for formulary decision makers.
Schafer JA; Kjesbo NK; Gleason PP
J Manag Care Pharm; 2009 May; 15(4):335-43. PubMed ID: 19422273
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes for prasugrel versus clopidogrel in patients with unstable angina or non-ST-elevation myocardial infarction: an analysis from the TRITON-TIMI 38 trial.
De Servi S; Goedicke J; Schirmer A; Widimsky P
Eur Heart J Acute Cardiovasc Care; 2014 Dec; 3(4):363-72. PubMed ID: 24818952
[TBL] [Abstract][Full Text] [Related]
8. The influence of smoking status on the pharmacokinetics and pharmacodynamics of clopidogrel and prasugrel: the PARADOX study.
Gurbel PA; Bliden KP; Logan DK; Kereiakes DJ; Lasseter KC; White A; Angiolillo DJ; Nolin TD; Maa JF; Bailey WL; Jakubowski JA; Ojeh CK; Jeong YH; Tantry US; Baker BA
J Am Coll Cardiol; 2013 Aug; 62(6):505-12. PubMed ID: 23602770
[TBL] [Abstract][Full Text] [Related]
9. Impact of CYP2C19 genetic testing on provider prescribing patterns for antiplatelet therapy after acute coronary syndromes and percutaneous coronary intervention.
Desai NR; Canestaro WJ; Kyrychenko P; Chaplin D; Martell LA; Brennan T; Matlin OS; Choudhry NK
Circ Cardiovasc Qual Outcomes; 2013 Nov; 6(6):694-9. PubMed ID: 24192573
[TBL] [Abstract][Full Text] [Related]
10. Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction.
Lee JH; Ahn SG; Lee JW; Youn YJ; Ahn MS; Kim JY; Yoo BS; Lee SH; Yoon J; Kim J; Choi E; Yoo SY; Hung OY; Samady H
Platelets; 2016 Jun; 27(4):301-7. PubMed ID: 26556524
[TBL] [Abstract][Full Text] [Related]
11. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
13. Prasugrel versus clopidogrel for patients with unstable angina or non-ST-segment elevation myocardial infarction with or without angiography: a secondary, prespecified analysis of the TRILOGY ACS trial.
Wiviott SD; White HD; Ohman EM; Fox KA; Armstrong PW; Prabhakaran D; Hafley G; Lokhnygina Y; Boden WE; Hamm C; Clemmensen P; Nicolau JC; Menozzi A; Ruzyllo W; Widimsky P; Oto A; Leiva-Pons J; Pavlides G; Winters KJ; Roe MT; Bhatt DL
Lancet; 2013 Aug; 382(9892):605-13. PubMed ID: 23953385
[TBL] [Abstract][Full Text] [Related]
14. An analysis of TRITON-TIMI 38, based on the 12 month recommended length of therapy in the European label for prasugrel.
Wilcox R; Iqbal K; Costigan T; Lopez-Sendon J; Ramos Y; Widimsky P
Curr Med Res Opin; 2014 Nov; 30(11):2193-205. PubMed ID: 25025610
[TBL] [Abstract][Full Text] [Related]
15. Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial.
Schulz S; Richardt G; Laugwitz KL; Mehran R; Gershlick AH; Morath T; Mayer K; Neudecker J; Tölg R; Ibrahim T; Hauschke D; Braun D; Schunkert H; Kastrati A; Mehilli J;
Clin Cardiol; 2014 May; 37(5):270-6. PubMed ID: 24633823
[TBL] [Abstract][Full Text] [Related]
16. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial.
Roberts JD; Wells GA; Le May MR; Labinaz M; Glover C; Froeschl M; Dick A; Marquis JF; O'Brien E; Goncalves S; Druce I; Stewart A; Gollob MH; So DY
Lancet; 2012 May; 379(9827):1705-11. PubMed ID: 22464343
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial.
Sardella G; Calcagno S; Mancone M; Palmirotta R; Lucisano L; Canali E; Stio RE; Pennacchi M; Di Roma A; Benedetti G; Guadagni F; Biondi-Zoccai G; Fedele F
Circ Cardiovasc Interv; 2012 Oct; 5(5):698-704. PubMed ID: 23048056
[TBL] [Abstract][Full Text] [Related]
18. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syndromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial.
Wiviott SD; Braunwald E; McCabe CH; Horvath I; Keltai M; Herrman JP; Van de Werf F; Downey WE; Scirica BM; Murphy SA; Antman EM;
Lancet; 2008 Apr; 371(9621):1353-63. PubMed ID: 18377975
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel.
Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA;
J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483
[TBL] [Abstract][Full Text] [Related]
20. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
